European Study Group on Interferon Beta-1b in Secondary Progressive
MS.Placebo-controlled multicenter
randomized trial of interferon beta-1b in treatment of secondary progressive multiple
sclerosis. Lancet1998;
352: 1491-1497.
2.
Goodkin, DE, et al. Low-dose
(7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive
multiple sclerosis. Annals of
Neurology1995; 37:
30-40.
3.
Hohlfeld R.Biotechnological
agents for the immunotherapy of multiple sclerosis. Principles, problems and
perspectives. Brain1997;
120(Pt 5): 865-916.
4.
Noseworthy JH , Vandervoort MK,
Penman
M., et al. Cyclophosphamide and plasma
exchange in multiple sclerosis.
Lancet1991; 337:
1540-1541.
5.
Weiner, HL, et al.
Intermittent cyclophosphamide pulse therapy in progressive multiple
sclerosis: Final report of the Northeast Cooperative Multiple Sclerosis Treatment
Group. Neurology1993; 43:
910-918.
6.
Rice Gpa for the Cladribine Clinical Study
Group; and Filippi M., Comi G. for the
Cladribine MRI Study
Group.Cladribine and progressive MS:
Clinical and MRI outcomes of a multicenter controlled trial.
Neurology2000; 54:
1145-1155.
